YOLFTbeta
06

Anterogen.Co.Ltd

065660 · KQ · Healthcare / Pharmaceuticals

13,610.00KRW-100.00 (-0.73%)

Price History

Full chart

Market Stats

Previous Close13,710.00
Open14,000.00
Day Range13,440.00 – 14,260.00
52-Week Range13,500.00 – 61,800.00
Volume17.20K
Market Cap149.59B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.47
50-Day Avg15,487.00
200-Day Avg30,636.40

About

Anterogen.Co.,Ltd., a bio-venture company, engages in the research, development, and commercialization of stem cell therapy products using adipose-derived stem cells in South Korea and internationally. The company offers medicines, including Cupistem injection, an adipose stem cell product that is used for the treatment of Crohn's fistula; Queencell, a stromal vascular fraction used for the regeneration of subcutaneous adipose tissue; and Remodulin injection, a medicine for the treatment of pulmonary arterial hypertension. It also provides cosmetics, such as hair care products comprising SCM2 and SCM2-Black; and skin care products, such as Therastem-Derma, Therastem-White Silk, and Therastem-White Glutathione, as well as human stem cell conditioned media, a cosmetic raw material. In addition, the company offers cell banking services; and analysis services that include sample analysis for clinical studies, as well as conducts biopharmaceutical tests for identification, purity, potency, adventitious virus, etc. Anterogen.Co.,Ltd. was founded in 2000 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • Employees0
  • HeadquartersNamsung Plaza, Seoul, South Korea, 08589, Korea
  • Websitehttp://anterogen.com

Financials

Income Statement

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.83B3.53B4.90B5.36B3.61B4.15B4.15B8.12B6.59B6.50B6.93B7.54B
Growth (%)-+92.57%+38.61%+9.42%-32.67%+14.98%+0.09%+95.64%-18.85%-1.38%+6.66%+8.71%
Cost of Revenue854.08M1.18B1.39B2.11B1.92B2.49B2.41B4.25B3.97B3.83B4.30B4.87B
Gross Profit980.20M2.35B3.50B3.25B1.69B1.66B1.74B3.87B2.62B2.67B2.63B2.66B
Gross Margin53.44%66.59%71.54%60.69%46.77%40.04%41.97%47.68%39.70%41.02%37.91%35.35%
Operating Expense2.57B2.48B3.40B3.39B4.18B6.39B4.48B6.51B7.25B8.12B6.43B5.10B
Operating Income-1.59B-125.23M102.64M-143.01M-2.49B-4.73B-2.74B-2.63B-4.63B-5.46B-3.80B-2.43B
Operating Margin-86.45%-3.55%2.10%-2.67%-69.00%-113.95%-66.06%-32.42%-70.25%-83.94%-54.88%-32.28%
EBITDA---------4.39B-484.44M-1.45B-1.84B
EBITDA Margin---------66.64%-7.45%-20.87%-24.41%
Net Income-1.42B-58.31M371.66M446.74M-961.76M-4.05B-4.38B-553.98M-6.84B-2.84B-2.29B-1.37B
Net Income Margin-77.18%-1.65%7.59%8.34%-26.66%-97.64%-105.39%-6.82%-103.73%-43.70%-33.07%-18.23%
R&D1.14B907.75M1.55B1.01B1.87B2.53B4.01B4.19B4.66B5.38B4.11B3.09B
R&D as % of Total Revenue62.29%25.70%31.56%18.91%51.84%61.07%96.52%51.65%70.68%82.82%59.24%41.01%
Interest Expense00000669.88M315.43M1.24B1.69B1.53B259.60M-
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%16.15%7.60%15.28%25.71%23.48%3.74%-

Balance Sheet

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets14.47B18.49B35.43B58.14B101.44B84.59B94.20B136.70B124.13B149.43B116.08B88.26B
Total Liabilities1.51B1.85B1.40B11.53B45.37B16.20B13.14B19.83B17.34B19.99B5.87B812.56M
Total Equity12.96B16.64B34.02B46.61B56.07B68.39B81.07B116.87B106.79B129.44B110.21B87.45B
Cash1.66B4.79B6.69B11.86B16.84B42.07B40.11B6.97B3.90B1.39B1.48B1.58B
Total Debt---9.32B10.33B-------
Net Debt------774.02M4.80B8.81B8.35B--

Cash Flow

Currency: KRW2014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.01B844.49M-130.65M379.21M-1.50B-1.65B-4.41B-3.05B-1.98B-1.99B-860.38M-1.02B
Investing Cash Flow1.59B-1.31B-14.95B-15.17B-37.68B27.24B-1.05B-14.37B-4.90M4.51B10.94B-
Financing Cash Flow3.60B3.60B16.94B20.01B44.14B-404.32M3.50B15.92B-1.01B-5.00B-10.00B-
Capital Expenditure156.08M659.00M6.06B637.46M3.55B2.99B5.72B3.33B1.48B203.28M311.59M265.81M
Free Cash Flow-------10.15B-6.58B-3.46B-2.19B-1.17B-1.29B
FCF to OCF------229.93%216.23%174.96%110.22%136.22%126.07%

Earnings

Report DateMay 19, 2016Aug 16, 2016Nov 11, 2016Feb 14, 2017May 10, 2017Aug 11, 2017Nov 13, 2017Feb 20, 2018May 11, 2018Aug 13, 2018Nov 14, 2018Feb 19, 2019May 14, 2019Aug 14, 2019Nov 13, 2019Jan 20, 2020May 14, 2020Aug 13, 2020Nov 12, 2020Jan 29, 2021Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------------------------------
EPS Actual154.38-48.9813.64-69.2383.96-39.6546.307.42-33.64-165.79-152.22217.44-126.4164.98-55.07-382.41-114.15-574.00131.00-107.55-309.51306.23-42.87-20.50-273.09-220.18-155.06-288.14-1.80-169.93-106.24-19.59-58.72-53.23-16.69-107.12-70.54-9.01-7.93-50.53-88.17-14.98
Surprise------------------------------------------
TimingPre-marketPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-market--After-hoursPre-marketAfter-hoursAfter-hours-----------------------

Key Statistics & Ratios

Market Cap149.59B
Enterprise Value104.40B
Trailing P/E0.00
Forward P/E0.00
Price / Sales17.50
Price / Book1.83
Revenue (TTM)7.54B
Gross Profit (TTM)3.84B
EBITDA-3.30B
Profit Margin-85.60%
Operating Margin-54.47%
Return on Equity-231.75%
Return on Assets-2.02%
Shares Outstanding7.95M
Shares Float7.54M
Beta0.47
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%